"Treatment of HIV infected patients with the only currently approved anti-HIV integrase drug results in the selection of viruses that are resistant to that drug.
Avexa's lead anti-integrase compounds are able to inhibit these integrase inhibitor resistant HIV because they interact with the HIV-integrase in a different way to the marketed drug."
Whilst Avx can't give alot of info out understandably, the comments are very positive and point to Avx having something better than what's on the market. This is very positive and greatly enhances the chances of a Tibotec deal.
AVX Price at posting:
16.5¢ Sentiment: Hold Disclosure: Held
